Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy in Squamous Non–Small-Cell Lung Cancer in China

Abstract

Purpose The five-year update data from the KEYNOTE-407 study have unveiled noteworthy improvements in survival outcomes achieved with pembrolizumab plus chemotherapy (Pembro+Chemo) compared to placebo plus chemotherapy (Placebo+Chemo) for patients with previously untreated metastatic squamous non-small cell lung cancer (NSCLC). Building upon this finding, our study sought to evaluate the cost-effectiveness of Pembro+Chemo, utilizing the latest available data, from the perspective of the Chinese health care system. Patients and Methods A Markov model was employed to compare the quality-adjusted life-year (QALY), life-year (LY), total cost, and incremental cost-effectiveness ratio (ICER) between Pembro+Chemo and Placebo+Chemo. The clinical and safety data were derived from the five-year update date of the KEYNOTE-407 study. Sensitivity analyses were conducted to assess the uncertainty of the model, and additional subgroup analyses were performed to explore specific subpopulations. Results For patients with previously untreated metastatic squamous NSCLC, the utilization of Pembro+Chemo resulted in a improvement of 0.61 quality-adjusted life years (QALYs) along with a cost reduction of $17,491.52 when compared to Placebo+Chemo. Notably, across various subgroups with different tumor proportion scores (TPS), Pembro+Chemo demonstrated enhanced QALYs and lower total costs. Conclusion From the perspective of the Chinese health care system, first-line Pembro+Chemo emerges as a dominant treatment option over Placebo+Chemo for the treatment of metastatic squamous NSCLC.

Cost-effectiveness of Kang Ai injection plus chemotherapy vs. Shenqi Fuzheng injection plus chemotherapy in the first-line treatment of advanced non-small cell lung cancer

“…Under appropriate assumptions, it is convenient to simulate patients’ long-term health state changes. Many published studies built a three-state Markov model to evaluate the cost-effectiveness of drugs for patients with NSCLC ( 17 – 20 ). This demonstrated the suitability of the Markov model.…”

Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China

“…It was initially postulated that patients started in the PFS state, but they could either progress to PD, die, or remain in the PFS state. 22 Transition probabilities for PFS and OS in both the tislelizumab-chemotherapy group and the placebo-chemotherapy group were sourced from the RATIONALE-306 clinical trial. These probabilities were extrapolated beyond the model's time horizon using conventional statistical techniques as detailed by Guyot.…”

Cost-Effectiveness of First-Line Atezolizumab versus Chemotherapy in Non-Small-Cell Lung Cancer Patients Ineligible for Platinum-Containing Regimens

“…1,2 In terms of both incidence and mortality, lung cancer takes precedence among all types of cancers, accounting for approximately 22% of cancer-related deaths in China. [3][4][5][6] Nonsmall cell lung cancer (NSCLC) represents the majority, ranging 85% to 90%, 7,8 of all lung cancers cases, with nearly 60% of NSCLC patient already diagnosed at an advanced stages. [9][10][11] According to the Chinese Society of Clinical Oncology guidelines for NSCLC (2023 edition), platinum-based chemotherapy doublets remain the primary treatment strategy for advanced NSCLC patients who not possess epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase-positive (ALK) mutations.…”